Kline Teresa L.

SEC source: 0000075252-26-000028 · form4.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,316

F1 · security: Restricted stock grant which vests the earlier of (i) one year from the grant date and (ii) the date of the next annual meeting that is at least 50 weeks following the grant date.

SEC source: 0000896262-25-000083 · wk-form4_1755201763.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax.

F2 · shares: Includes 1,690 time-based Restricted Stock Units ("RSUs") of the Issuer that were outstanding at the Effective Time that were cancelled and converted into the right to receive the Per Share Merger Consideration for each such outstanding RSU as of the Effective Time.

F1 · price: On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax.

F2 · price: Includes 1,690 time-based Restricted Stock Units ("RSUs") of the Issuer that were outstanding at the Effective Time that were cancelled and converted into the right to receive the Per Share Merger Consideration for each such outstanding RSU as of the Effective Time.

SEC source: 0001062993-25-009728 · form4.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,125

F1 · security: Restricted stock grant which vests the earlier of (i) one year from the grant date and (ii) the date of the next annual meeting that is at least 50 weeks following the grant date.

SEC source: 0000896262-25-000044 · wk-form4_1746575335.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,818

F1 · shares: The Issuer awarded the Reporting Person 1,690 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on May 3, 2026, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date.

SEC source: 0001062993-24-009886 · form4.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,211

F1 · security: Restricted stock grant which vests the earlier of (i) one year from the grant date and (ii) the date of the next annual meeting that is at least 50 weeks following the grant date.

SEC source: 0000896262-24-000027 · wk-form4_1715129971.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,128

F1 · shares: The Issuer awarded the Reporting Person 1,678 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on May 3, 2025, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date.

SEC source: 0001062993-23-011001 · form4.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,057

F1 · security: Restricted stock grant which vests the earlier of (i) one year from the grant date and (ii) the date of the next annual meeting that is at least 50 weeks following the grant date.

SEC source: 0000896262-23-000051 · wf-form4_168333616638182.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,450

F1 · shares: The Issuer awarded the Reporting Person 1,941 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on May 3, 2024, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date.

SEC source: 0000896262-22-000041 · wf-form4_165515267293389.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,509

F1 · shares: The Issuer awarded the Reporting Person 1,304 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on June 9, 2023, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date.

SEC source: 0001062993-22-014073 · form4.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,713

F1 · security: Restricted stock grant which vests in one year.

SEC source: 0001562180-22-004070 · primarydocument.xml · derivative · entry 11

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,787 shares

Expires 2027-07-31

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

SEC source: 0001562180-22-004070 · primarydocument.xml · derivative · entry 10

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,797 shares

Expires 2028-01-16

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

SEC source: 0001562180-22-004070 · primarydocument.xml · derivative · entry 9

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,473 shares

Expires 2028-06-04

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

SEC source: 0001562180-22-004070 · primarydocument.xml · derivative · entry 8

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,666 shares

Expires 2030-06-03

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

SEC source: 0001562180-22-004070 · primarydocument.xml · derivative · entry 7

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,734 shares

Expires 2031-06-02

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

SEC source: 0001562180-22-004070 · primarydocument.xml · derivative · entry 6

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,390 shares

Expires 2031-03-15

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

SEC source: 0001562180-22-004070 · primarydocument.xml · derivative · entry 5

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,172 shares

Expires 2029-06-03

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

SEC source: 0001562180-22-004070 · primarydocument.xml · derivative · entry 4

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,355 shares

Expires 2030-01-16

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

SEC source: 0001562180-22-004070 · primarydocument.xml · derivative · entry 3

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,220 shares

Expires 2029-01-15

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

SEC source: 0001562180-22-004070 · primarydocument.xml · nonDerivative · entry 2

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.

SEC source: 0001562180-22-004070 · primarydocument.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,239

F1 · kind: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes].

F1 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes].

SEC source: 0000899243-22-012669 · doc4.xml · derivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,059 shares

Expires not disclosed

F2 · derivative.exercise_price: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee.

F1 · kind: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F3 · kind: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration.

F3 · price: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration.

F4 · derivative.exercise_date: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date.

F4 · derivative.expiration_date: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date.

SEC source: 0000899243-21-023707 · doc4.xml · derivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,059

Underlying: Common Stock · 5,059 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer ("Common Stock"). The restricted stock units will be settled in either Common Stock or cash (or a combination thereof) at the discretion of the Issuer's compensation committee.

F2 · derivative.exercise_date: These restricted stock units vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date.

F2 · derivative.expiration_date: These restricted stock units vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date.

SEC source: 0000896262-21-000093 · wf-form4_162336222697162.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,205

F1 · shares: The Issuer awarded the Reporting Person 574 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on June 8, 2022, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date.

SEC source: 0001562180-21-004112 · primarydocument.xml · derivative · entry 2

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,734

Underlying: Common Stock · 5,734 shares

Expires 2031-06-02

F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 3, 2021.

SEC source: 0001562180-21-004112 · primarydocument.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,076

F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 3, 2022.

F2 · balance_after: Includes 3,239 restricted stock units.

SEC source: 0001562180-21-002361 · primarydocument.xml · derivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,390

Underlying: Common Stock · 3,390 shares

Expires 2031-03-15

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2021.

SEC source: 0000899243-20-016248 · doc4.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,631

F1 · shares: The Issuer awarded the Reporting Person 851 time-based Restricted Stock Units, each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest 100% on June 9, 2021, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date.

SEC source: 0001562180-20-004318 · primarydocument.xml · derivative · entry 2

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,666

Underlying: Common Stock · 9,666 shares

Expires 2030-06-03

F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2020.

SEC source: 0001562180-20-004318 · primarydocument.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,837

F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2021.

F2 · balance_after: Includes 5,011 restricted stock units.

SEC source: 0000899243-20-008943 · doc4.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,780

SEC source: 0001562180-20-000478 · primarydocument.xml · derivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,355

Underlying: Common Stock · 3,355 shares

Expires 2030-01-16

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2020.

SEC source: 0000899243-19-028191 · doc4.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 780

F1 · shares: The shares reported are subject to time-based vesting conditions and will vest 100% on June 7, 2020, predicated upon the Reporting Person's continued service as a non-employee member of the Issuer's Board of Directors through the vesting date.

SEC source: 0001562180-19-003397 · primarydocument.xml · derivative · entry 2

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,172

Underlying: Common Stock · 5,172 shares

Expires 2029-06-03

F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2019.

SEC source: 0001562180-19-003397 · primarydocument.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,826

F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2020.

F2 · balance_after: Includes 2,312 restricted stock units.

SEC source: 0001562180-19-000367 · primarydocument.xml · derivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,220

Underlying: Common Stock · 3,220 shares

Expires 2029-01-15

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2019.

SEC source: 0001562180-18-002917 · primarydocument.xml · derivative · entry 2

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,473

Underlying: Common Stock · 3,473 shares

Expires 2028-06-04

F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 5, 2018.

SEC source: 0001562180-18-002917 · primarydocument.xml · nonDerivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,514

F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 5, 2019.

F2 · balance_after: Includes 1,514 RSUs.

SEC source: 0001562180-18-000370 · primarydocument.xml · derivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,797

Underlying: Common Stock · 2,797 shares

Expires 2028-01-16

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2018.

SEC source: 0001562180-17-002595 · primarydocument.xml · derivative · entry 1

Kline Teresa L. · CIK 0001712647 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,787

Underlying: Common Stock · 13,787 shares

Expires 2027-07-31

F1 · derivative.exercise_date: The vesting commencement date of the option is August 1, 2017. 25% of the shares subject to the option shall vest on August 1, 2018 and 1/48th of the shares subject to the option shall vest monthly thereafter over three (3) years.